-
Mashup Score: 1ASH Clinical News | American Society of Hematology - 7 month(s) ago
An analysis of 994 patients with AML shows that treatment with venetoclax plus low-intensity or intensive chemotherapy attenuates the negative prognostic impact of AML with a splicing factor mutation. Akshat Jain, MD, MPH, a pediatric hematologist at Loma Linda University School of Medicine and Children’s Hospital in California, shares a recent poem of his that was written in tribute to patients with sickle cell disease. A pooled analysis of 11 trials found that half of patients with MM who were treated
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Based on the recommendation of an independent data monitoring committee and positive topline data, accrual in the KMT2A-rearranged cohorts of the AUGMENT-101 trial of revumenib will be stopped.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Revumenib produced complete remissions in adult and pediatric patients with relapsed/refractory #AML or #ALL harboring KMT2A rearrangements, meeting the primary end point of the phase 1/2 AUGMENT-101 trial. #leusm | @MSKCancerCenter https://t.co/YCWceek4Qv
-
-
Mashup Score: 0Marlise Luskin,MD, MSCE [slides]-Venetoclax and BCL2 Inhibitors - 7 month(s) ago
Marlise Luskin,MD, MSCE- Medical Oncology- Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship Program and education director for the adult leukemia program. The presentation focused on the use of the drug venetoclax (and its related drugs) in the treatment of acute lymphoblastic leukemia (ALL), particul…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dive into the potential of #venetoclax & #BCL2 inhibitors reshaping #ALL treatment! Join Dr. Marlise Luskin as she explores breakthroughs & synergies. Exciting advancements await! [slides][video]https://t.co/yXXpX2m7vi ➡️ Watch now! @_MDEducation @Ryan_fitzpatric #Leukemia https://t.co/AA4f0StMX5
-
-
Mashup Score: 0Bijal Shah,MD,MS[slides] UPD-CART Cell Therapy for Refractory ALL - 7 month(s) ago
Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell therapy for patients with relapsed refractory conditions, particularly those who have experienced multiple relapses and high tumor burdens. They highlight the success achieved with CAR T t…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Discover positive outcomes of CAR T therapy in relapsed refractory ALL with insights from Bijal Shah MD, MS. Integrated approaches including #Blinatumomab & Inotuzumab Ozogamicin. 🌟 #CAR_T #ALL [slides][video] https://t.co/CGcCjlaWQY @_MDEducation @Ryan_fitzpatric" https://t.co/WA9gpp0yNz
-
-
Mashup Score: 0Shira N. Dinner, MD [slides]- Therapies for Older Adult ALL - 7 month(s) ago
Shira N. Dinner, MD- Robert H Lurie Cancer Center Shira N. Dinner, MD discussed several studies focused on the treatment of acute lymphoblastic leukemia (ALL) in older adults, particularly those aged 55 and above. The presentation highlighted the challenges and outcomes associated with different treatment approaches…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Discover how Shira N. Dinner, MD discusses the revolutionizing treatment for older adult ALL with #Blinatumomab & Inotuzumab. Learn about novel strategies improving outcomes. [slides][video] 👉 https://t.co/sgeDbDJHGk @_MDEducation @Ryan_fitzpatric @LurieCancer #ALL 👆 https://t.co/jSMp2rX8oW
-
-
Mashup Score: 0Hagop Kantarjian, MD[slides]- ALL Treatment:Therapies-Strategies - 7 month(s) ago
Hagop Kantarjian, MD is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center Hagop Kantarjian, MD shared exciting updates and progress in the treatment landscape. Notably, some of the predictions made back in 2010 are now proving to be successful. Initiatives like th…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Blinatumomab & Inotuzumab excel, 'Brick Regimen' introduced by @DrHKantarjian innovates, CAR T-cell therapy revolutionizes. Dive into acute lymphoblastic leukemia advances with @_MDEducation @Ryan_fitzpatric & @MDAndersonNews. [slides][video]👉 https://t.co/pl92iMLmF8 #ALL https://t.co/ckXQkDKrUy
-
-
Mashup Score: 5Offering Hope through Better Treatments and Care - 7 month(s) ago
Learn how advances in cancer treatment and care have improved patients’ quality of life.
Source: www.cancer.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
After being diagnosed with acute lymphoblastic leukemia at age 5 and relapsing twice, Emily appeared to be out of treatment options. Research advances gave Emily her health back. https://t.co/bijEZsIBlp #ALL #ThisIsWhy https://t.co/lpkjtsklcS
-
-
Mashup Score: 0Charles Mullighan,MD[slides]-Genomic Classification-Corrected - 8 month(s) ago
Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children’s Research Hospital Charles Mullighan, MD, delves into the genomic classification of Acute Lymphoblastic Leukemia (ALL) and its diagnostic approaches. He covers three main area…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Explore Acute Lymphoblastic Leukemia insights by Charles Mullighan, MD! Learn about genomic classification, diagnostics, and more. 🧬 #ALL #Genomics [slides][video] https://t.co/2aoU8Ienvu ➡️ @_MDEducation @Ryan_fitzpatric https://t.co/bP0utDRKlF
-
-
Mashup Score: 0
Ongoing clinical trials seek to improve minimal residual disease-negative rates and further improve event-free survival.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Kristen O’Dwyer, MD, discussed monoclonal antibodies and small molecule therapies combined with high-dose chemotherapy for adult #ALL. #leusm #SOHO23 https://t.co/TtqgHmv8ET
-
-
Mashup Score: 8Ponatinib Increases MRD-Negative CR Rate in Ph+ ALL - 8 month(s) ago
The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“This study has established ponatinib as the standard of care for Ph-positive acute lymphoblastic leukemia,” says our Dr. Elias Jabbour of findings from the Phase III PhALLCON trial presented at #SOHO23. Learn more: https://t.co/PB5eyY547O @onclive #ALL #LeuSM #EndCancer
-
The October issue is here! 🩸 This month, read about the unique challenges of treating adolescent blood cancer patients, outpatient hematopoietic cell #transplantation in a Mexican clinic, a new #ALL treatment approved by the #FDA, and more! https://t.co/J3USedjRCK https://t.co/iHheblVyD6